المؤلفون: A. G. Chuchalin, S. N. Avdeev, Z. R. Aisanov, O. P. Baranova, S. E. Borisov, N. A. Geppe, A. A. Vizel’, I. Yu. Vizel’, A. A. Zaicev, N. Y. Kravchenko, M. M. Ilkovich, O. V. Lovacheva, A. B. Malakhov, A. G. Malyavin, D. V. Petrov, V. V. Romanov, I. V. Sivokozov, M. V. Samsonova, I. P. Solovieva, I. E. Stepanyan, S. A. Terpigorev, I. E. Tyurin, L. Ya. Frantsuzevich, A. L. Chernyaev, E. I. Shmelev, N. M. Shmeleva, А. Г. Чучалин, С. Н. Авдеев, З. Р. Айсанов, О. П. Баранова, С. Е. Борисов, Н. А. Геппе, А. А. Визель, И. Ю. Визель, А. А. Зайцев, Н. Ю. Кравченко, М. М. Илькович, О. В. Ловачева, А. Б. Малахов, A. Г. Малявин, Д. В. Петров, В. В. Романов, И. В. Сивокозов, М. В. Самсонова, И. П. Соловьева, И. Э. Степанян, С. А. Терпигорев, И. Е. Тюрин, Л. Я. Французевич, А. Л. Черняев, Е. И. Шмелев, Н. М. Шмелева

المصدر: PULMONOLOGIYA; Том 32, № 6 (2022); 806-833 ; Пульмонология; Том 32, № 6 (2022); 806-833 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: лечение, diagnosis, clinical manifestations, treatment, диагностика, клинические проявления

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4155/3472; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4155/1566; Визель А.А., ред. Саркоидоз. М.: Атмосфера; 2010.; ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 1999; 14 (4): 735–737. DOI:10.1034/j.1399-3003.1999.14d02.x.; Landi C., Carleo A., Cillis G., Rottoli P. Sarcoidosis: proteomics and new perspectives for improving personalized medicine. Expert Rev. Proteomics. 2018; 15 (10): 829–835. DOI:10.1080/14789450.2018.1528148.; Besnard V., Calender A., Bouvry D. et al. G908R NOD2 variant in a family with sarcoidosis. Respir. Res. 2018; 19 (1): 44. DOI:10.1186/s12931-018-0748-5.; Хоменко А.Г., Швайгер О., ред. Саркоидоз. М.: Медицина; 1982.; Zhao M.M., Du S.S., Li Q.H. et al. High throughput 16SrRNA gene sequencing reveals the correlation between Propionibacterium acnes and sarcoidosis. Respir. Res. 2017; 18 (1): 28. DOI:10.1186/s12931-017-0515-z.; van Dee L., Stehouwer M., van Bemmel T. Systemic sarcoidosis associated with exposure to Borrelia burgdorferi in a 21-year-old man. Eur. J. Case Rep. Intern. Med. 2018; 5 (10): 000942. DOI:10.12890/2018_000942.; Esteves T., Aparicio G., Garcia-Patos V. Is there any association between sarcoidosis and infectious agents? a systematic review and meta-analysis. BMC Pulm. Med. 2016; 16 (1): 165. DOI:10.1186/s12890-016-0332.; García Ródenas M.D.M., Gayá García-Manso I., García Sevila R. Sarcoidosis associated with Interferon beta treatment. Med. Clin. (Barc). 2019; 153 (5): e21–22. DOI:10.1016/j.medcli.2018.11.021.; Визель А.А., Визель И.Ю. Саркоидоз и интерфероны: звенья патогенеза и ятрогения. Практическая пульмонология. 2017; (1): 46–50. Доступно на: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_1_2017_46.pdf; Bargagli E., Prasse A. Sarcoidosis: a review for the internist. Intern. Emerg. Med. 2018; 13 (3): 325–331. DOI:10.1007/s11739-017-1778-6.; Baughman R.P., Culver D.A., Judson M.A. A concise review of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 2011; 183 (5): 573–581. DOI:10.1164/rccm.201006-0865ci.; Patterson K.C., Chen E.S. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest. 2018; 153 (6): 1432–1442. DOI:10.1016/j.chest.2017.11.030.; Hu Y., Yibrehu B., Zabini D., Kuebler W.M. Animal models of sarcoidosis. Cell Tissue Res. 2017; 367 (3): 651–661. DOI:10.1007/s00441-016-2526-3.; Dubaniewicz A. [“Danger theory”as a common mechanism of sarcoidosis induction by infectious and non-infectious factors – a role of environmental factors and autoimmunity]. Pol. Merkur. Lekarski. 2018; 44 (261): 97–100. Available at: https://www.researchgate.net/publication/324130127_Danger_theory_as_a_common_mechanism_of_sarcoidosis_induction_by_infectious_and_non-infectious_factors_-_a_role_of_genetics_factors; Jouni H., Chareonthaitawee P. Unraveling inflammation and oxidative stress in cardiac sarcoidosis. Circ. Cardiovasc. Imaging. 2017; 10 (12): e007287. DOI:10.1161/CIRCIMAGING.117.007287.; Ruža I., Lucāne Z. Serum and urinary calcium level in Latvian patients with sarcoidosis. Reumatologia. 2018; 56 (6): 377–381. DOI:10.5114/reum.2018.80715.; Suzuki T., Tsushima K., Kawata N. et al. Estimation using the impulse oscillation system in patients with pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2015; 32 (2): 144–150. Available at: https://www.researchgate.net/publication/280876634_Estimation_Using_The_Impulse_Oscillation_System_In_Patients_With_Pulmonary_Sarcoidosis; Евфимьевский В.П., Борисов С.Е., Богородская Е.М. Нарушения дыхательной функции при гранулематозах и распространенных поражениях иной природы: пособие для врачей. М.; 1998.; Van Schalkwyk E.M., Bezuidenhout J., Wyser C.P. et al. Comparison of bronchoalveolar lavage, open lung biopsy and lung function in sarcoidosis. Eur. Resp. J. 1997; 10 (Suppl. 25): 206s. Available at: https://eurekamag.com/research/030/633/030633831.php; Ungprasert P., Matteson E.L. Neurosarcoidosis. Rheum. Dis. Clin. North Am. 2017; 43 (4): 593–606. DOI:10.1016/j.rdc.2017.06.008.; Duong H., Bonham C.A. Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment. Clin. Pulm. Med. 2018; 25 (2): 52–60. DOI:10.1097/CPM.0000000000000252.; Русаков Н.В., Мухин Н.А, Брико Н.И. и др. Особенности распространения саркоидоза в условиях Москвы. Гигиена и санитария. 2012; (4): 16–18. Доступно на: https://cyberleninka.ru/article/n/osobennosti-rasprostraneniya-sarkoidoza-v-usloviyah-moskvy?ysclid=l-93wqbcyxo307456749; Баранова О.П., Рефицкая Н.В., Степаненко Т.А. и др. Эпидемиология саркоидоза органов дыхания в Санкт-Петербурге (1998–2008). В кн.: Чучалин А.Г., ред. XIX Национальный Конгресс по болезням органов дыхания: cборник трудов. М.: ДизайнПресс; 2009: 216–217.; Петров Д.В., Овсянников Н.В., Коненко А.Ю., и др. Результаты внедрения «Порядка оказания медицинской помощи больным саркоидозом» в городе Омске. Вестник современной клинической медицины. 2013; 6 (2): 42–46. Доступно на: https://cyberleninka.ru/article/n/rezultaty-vnedreniya-poryadka-okazaniya-meditsinskoy-pomoschi-bolnym-sarkoidozom-v-gorode-omske/viewer; Визель И.Ю., Визель А.А. Характеристика регистра больных саркоидозом в Республике Татарстан. Вестник современной клинической медицины. 2015; 8 (5): 18–26. Доступно на: http://vskmjournal.org/images/Files/Issues_Archive/2015/Issue_5/VSKM_2015_N_5_p18-26.pdf; Крюков Е.В., Антипушина Д.Н., Зайцев А.А. Саркоидоз – актуальная проблема различных силовых ведомств. Вестник Российской военно-медицинской академии. 2016; 56 (4): 224–227.; Baughman R.P., Field S., Costabel U. et al. Sarcoidosis in America. Analysis based on health care use. Ann. Am. Thorac. Soc. 2016; 13 (8): 1244–1252. DOI:10.1513/annalsats.201511-760oc.; Thomeer M., Demedts M., Vandeurzen K. et al. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin. Belg. 2001; 56 (3): 163–172. DOI:10.1179/acb.2001.026.; Morimoto T., Azuma A., Abe S. et al. Epidemiology of sarcoidosis in Japan. Eur. Respir. J. 2008; 31 (2): 372–379. DOI:10.1183/09031936.00075307.; Hoffman A.L., Milman N., Byg K.E. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93 (1): 30–36. DOI:10.1111/j.1651-2227.2004.tb00670.x.; Terwiel M., van Moorsel C.H.M. Clinical epidemiology of familial sarcoidosis: a systematic literature review. Respir. Med. 2019; 149: 36–41. DOI:10.1016/j.rmed.2018.11.022.; Визель И.Ю., Шмелев Е.И., Визель А.А., Ганибаева Г.С. Сравнение вновь выявленных больных саркоидозом молодого и старшего возраста. Русский медицинский журнал. 2018; 10 (1): 16–20. Доступно на: https://www.rusmedreview.com/articles/bolezni_dykhatelnykh_putey/Sravnenie_vnovy_vyyavlennyh_bolynyh_sarkoidozom_molodogo_istarshego_vozrasta/; Терпигорев С.А., Эль Зейн Б.А., Верещагина В.М., Палеев Н.Р. Саркоидоз и проблемы его классификации. Вестник РАМН. 2012; (5): 30–37. Доступно на: https://cyberleninka.ru/article/n/sarkoidoz-i-problemy-ego-klassifikatsii/viewer; Bahmer T., Watz H., Develaska M. et al. Physical activity and fatigue in patients with sarcoidosis. Respiration. 2018; 95 (1): 18–26. DOI:10.1159/000481827.; Илькович М.М., Баранова О.П. Саркоидоз органов дыхания. В кн.: Илькович М.М., ред. Интерстициальные и орфанные заболевания легких. М.: ГЭОТАР-Медиа; 2019: 163–234.; Рабухин А.Е., Доброхотова М.Н., Тонитрова Н.С. Саркоидоз. М., Медицина; 1975.; Wanat K.A., Rosenbach M. Cutaneous sarcoidosis. Clin. Chest Med. 2015; 36 (4): 685–702. DOI:10.1016/j.ccm.2015.08.010.; Matsou A., Tsaousis K.T. Management of chronic ocular sarcoidosis: challenges and solutions. Clin. Ophthalmol. 2018; 12: 519–532. DOI:10.2147/OPTH.S128949.; Judson M.A. The clinical features of sarcoidosis: a comprehensive review. Clin. Rev. Allergy Immunol. 2015; 49 (1): 63–78. DOI:10.1007/s12016-014-8450-y.; Madaule S., Lauque D., Sailler L. et al. [Splenomegaly in sarcoidosis: clinical features and outcome. Analysis of 17 cases]. Rev. Med. Interne. 2004; 25 (5): 348–356. DOI:10.1016/j.revmed.2003.11.007 (in French).; Löffler C., Bergner R. [Sarcoidosis: renal manifestations]. Z. Rheumatol. 2017; 76 (5): 398–407. DOI:10.1007/s00393-017-0301-9 (in German).; Bechman K., Christidis D., Walsh S. et al. A review of the musculo-skeletal manifestations of sarcoidosis. Rheumatology (Oxford). 2018; 57 (5): 777–783. DOI:10.1093/rheumatology/kex317.; Chapman M.N., Fujita A., Sung E.K. et al. Sarcoidosis in the head and neck: an illustrative review of clinical presentations and imaging findings. AJR Am. J. Roentgenol. 2017; 208 (1): 66–75. DOI:10.2214/AJR.16.16058.; Иванова Д.А., Борисов С.Е., Недоступ А.В., Паша С. Поражение сердца при саркоидозе: диагностика латентных и клинически проявляющихся форм. Врач. 2008; (10): 28–33. Доступно на: https://www.elibrary.ru/download/elibrary_12924028_48123605.pdf; Dubrey S., Sharma R., Underwood R. et al. Sarcoidosis of the cardio-pulmonary systems. Clin. Med. (Lond.). 2016; 16 (1): 34–41. DOI:10.7861/clinmedicine.16-1-34.; Суслина З.А., Кистенёв Б.А., Максимова М.Ю., Моргунов В.А. Нейросаркоидоз. М.: МЕДпресс-информ; 2009.; Ibitoye R.T., Wilkins A., Scolding N.J. Neurosarcoidosis: a clinical approach to diagnosis and management. J. Neurol. 2017; 264 (5): 1023–1028. DOI:10.1007/s00415-016-8336-4.; Stern B.J., Royal W. 3rd, Gelfand J.M. et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018; 75 (12): 1546–1553. DOI:10.1001/jamaneurol.2018.2295.; Block N.L., Kava B.R. Genitourinary sarcoidosis: an essential review for the practicing clinician. Indian J. Urol. 2017; 33 (1): 6–12. DOI:10.4103/0970-1591.195724.; Ghrenassia E., Mekinian A., Chapelon-Albric C. et al. Digestive-tract sarcoidosis: French nationwide case-control study of 25 cases. Medicine (Baltimore). 2016; 95 (29): e4279. DOI:10.1097/md.0000000000004279.; Sahu P., Sharma S., Sharma N. et al. Unusual clinical presentations in early-onset childhood sarcoidosis: a correlation or coincidence? J. Clin. Diagn. Res. 2017; 11 (8): WD01–03. DOI:10.7860/JCDR/2017/27841.10389.; Fretzayas A., Moustaki M., Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis. World J. Pediatr. 2011; 7 (2): 103–110. DOI:10.1007/s12519-011-0261-0.; Николаев А.В. Сравнительная оценка показателей неспецифического, клеточного и гуморального иммунитета у больных туберкулезом и саркоидозом легких. Вестник Новгородского государственного университета. 2019; 115 (3): 36–41. DOI:10.34680/2076-8052.2019.3(115).36-41; Hoffmann A. L., Milman N., Byg K. E. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93 (1): 30–36. DOI:10.1080/08035250310007213.; Kempisty A., Białas-Chromiec B., Borkowska D., Kuś J. Interferon gamma release assays based on M. tuberculosis-specific antigens in sarcoidosis patients. Pneumonol. Alergol. Pol. 2015; 83 (2): 126–134. DOI:10.5603/PiAP.2015.0020.; Gupta D., Kumar S., Aggarwal A.N. et al. Interferon gamma release assay (QuantiFERON-TB Gold in Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28 (2): 95–101. Available at: https://www.researchgate.net/publication/51834535_Interferon_gamma_release_assay_QuantiFERON-TB_Gold_In_Tube_in_patients_of_sarcoidosis_from_a_population_with_high_prevalence_of_tuberculosis_infection; Nosal A., Schleissner L.A., Mishkin F.S., Lieberman J. Angiotensin-I-converting enzyme and gallium scan in noninvasive evaluation of sarcoidosis. Ann. Intern. Med. 1979; 90 (3): 328–331. DOI:10.7326/0003-4819-90-3-328.; Baughman R.P., Shipley R., Eisentrout C.E. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung. 1987; 165 (6): 371–377. DOI:10.1007/bf02714452.; Abe S., Munakata M., Nishimura M. et al. Gallium-67 scintigraphy, bronchoalveolar lavage, and pathologic changes in patients with pulmonary sarcoidosis. Chest. 1984; 85 (5): 650–655. DOI:10.1378/chest.85.5.650.; Okayama K., Kurata C., Tawarahara K. et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995; 107 (2): 330–334. DOI:10.1378/chest.107.2.330.; Bekerman C., Szidon J. P., Pinsky S. The role of gallium-67 in the clinical evaluation of sarcoidosis. Semin. Roentgenol. 1985; 20 (4): 400–409. DOI:10.1016/0037-198x(85)90047-1.; Jerusalem G., Beguin Y., Fassotte M.F. et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999; 94 (2): 429–433. Available at: https://www.researchgate.net/publication/12077850_Whole-body_positron_emission_tomography_using_18F-fluorodeoxyglucose_compared_to_standard_procedures_for_staging_patients_with_Hodgkins_disease; Ozer O., Eskazan A.E., Ar M.C. et al. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. J. Med. Case Rep. 2009; 3: 7306. DOI:10.4076/1752-1947-3-7306.; Dziedzic D.A., Peryt A., Orlowski T. The role of EBUS-TBNA and standard bronchoscopic modalities in the diagnosis of sarcoidosis. Clin. Respir. J. 2017; 11 (1): 58–63. DOI:10.1111/crj.12304.; Millward K., Fiddler C.A., Thillai M. Update on sarcoidosis guidelines. Curr. Opin. Pulm. Med. 2021; 27 (5): 484–489. DOI:10.1097/MCP.0000000000000807.; Demir O.F., Onal O. Is mediastinoscopy an effective diagnostic method in mediastinal area evaluation in pediatric patients? Asian. J. Surg. 2020; 43 (6): 690–695. DOI:10.1016/j.asjsur.2019.09.012.; Yoon H.Y., Kim H.M., Kim Y.J., Song J.W. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir. Res. 2018; 19 (1): 158. DOI:10.1186/s12931-018-0871-3.; Verleden S.E., Vanstapel A., De Sadeleer L. et al. Distinct airway involvement in subtypes of end-stage fibrotic pulmonary sarcoidosis. Chest. 2021; 160 (2): 562–571. DOI:10.1016/j.chest.2021.01.003.; Khan T., Selvakumar D., Trivedi S. et al. The value of endomyocardial biopsy in diagnosis and guiding therapy. Pathology. 2017; 49 (7): 750–756. DOI:10.1016/j.pathol.2017.08.004.; Zhang C., Chan K.M., Schmidt L.A., Myers J.L. Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis. Chest. 2016; 149 (2): 499–507. DOI:10.1378/chest.15-0615.; Buxbaum J., Papademetriou M., Klipfel N. et al. Biliary sarcoidosis: early diagnosis minimizes the need for surgery. Am. J. Respir. Crit. Care Med. 2013; 187 (5): 556–559. DOI:10.1164/ajrccm.187.5.556.; Siavelis H.A., Herrmann M.E., Aranha G.V. et al. Sarcoidosis and the pancreas. Surgery. 1999; 125 (4): 456–461. DOI:10.1016/S0039-6060(99)70014-0.; Manchanda A., Patel S., Jiang J.J., Babu A.R. Thyroid: an unusual hideout for sarcoidosis. Endocr. Pract. 2013; 19 (2): e40–43. DOI:10.4158/EP12131.CR.; James D.G., Jones Williams W., eds. Sarcoidosis and other granulomatous disorders. Philadelphia: Saunders; 1985: 163–166. DOI:10.1002/PPUL.1950010513.; Шмелев Е.И. Дифференциальная диагностика диссеминированных заболеваний легких неопухолевой природы. Русский медицинский журнал. 2001; (21): 919–922. Доступно на: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Differencialynaya_diagnostika_disseminirovannyh_zabolevaniy_legkih_neopuholevoy_prirody/; El Sayed F., Torbey G., Youssef H., Chababi M. Childhood sarcoidosis: diagnostic issues. Dermatol. Online J. 2013; 19 (10): 20037. DOI:10.5070/D31910020037.; Deverrière G., Flamans-Klein A., Firmin D. et al. [Early onset pediatric sarcoidosis, diagnostic problems]. Arch. Pediatr. 2012; 19 (7): 707–710. DOI:10.1016/j.arcped.2012.04.024.; Bradley B., Branley H.M., Egan J.J. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63: v1–58. DOI:10.1136/thx.2008.101691.; Baughman R., Drent M., Judson M. et al. Sarcoidosis treatment guidelines. Available at: https://stopsarcoidosis.org/wp-content/uploads/2013/03/FSR-Physicians-Protocol1.pdf; Balasubramanian A., Wade S.W., Adler R.A. et al. Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J. Bone Miner Res. 2018; 33 (10): 1881–1888. DOI:10.1002/jbmr.3523.; James W.E., Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev. Clin. Pharmacol. 2018; 11 (7): 677–687. DOI:10.1080/17512433.2018.1486706.; Baughman R.P., Nunes H., Sweiss N.J. et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur. Respir. J. 2013; 41 (6): 1424–1438. DOI:10.1183/09031936.00060612.; Soto-Gomez N., Peters J.I., Nambiar A.M. Diagnosis and management of sarcoidosis. Am. Fam. Physician. 2016; 93 (10): 840–850. https://www.aafp.org/pubs/afp/issues/2016/0515/p840.html; Визель А. А., Калвер Д. А., Визель И. Ю. и др. Оценка влияния альфа-токоферола на течение впервые выявленного саркоидоза легких: сравнительное исследование. Туберкулез и болезни легких. 2020; 98 (10): 33–40. DOI:10.21292/2075-1230-2020-98-10-33-40.; Костина З.И. О результатах лечения саркоидоза легких. Проблемы туберкулеза. 1977; (8): 44–50.; Diallo B.D., Diot B., Flament T. et al. [The pentoxifylline, a corticosteroid sparing in the treatment of sarcoidosis: a case report]. Rev. Pneumol. Clin. 2018; 74 (1): 48–51. DOI:10.1016/j.pneumo.2017.08.014.; Refiskaya N.V., Stepanenko T.A., Jablonskiy P.K., Baranova O.P. The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis. Eur. Respir. J. 2006; 28 (Suppl. 50): E3134. Available at: https://www.ers-education.org/lr/show-details/?idP=8337; Визель А.А., Визель Е.А., Насретдинова Г.Р. и др. Оценка эффективности малых доз пентоксифиллина в сочетании с токоферола ацетатом при внутригрудном саркоидозе. Пульмонология. 2005; (1): 24–28. DOI:10.18093/0869-0189-2005-0-1-24-28.; Crommelin H.A., Vorselaars A.D., van Moorsel C.H. et al. Anti-TNF therapeutics for the treatment of sarcoidosis. Immunotherapy. 2014; 6 (10): 1127–1143. DOI:10.2217/imt.14.65.; О совершенствовании санаторно-курортной и реабилитационной помощи больным туберкулезом. Приказ Минздравмедпрома РФ № 291 от 19.07.96 Доступно на: https://tkrfkod.ru/zakonodatelstvo/prikaz-minzdravmedproma-rf-ot-19071996-n-291/; Визель А.А., Гурылева М.Э. Саркоидоз у детей. Педиатрия. Журнал имени Г.Н.Сперанского. 2004; 83 (2): 62–66. Доступно на: https://pediatriajournal.ru/files/upload/mags/263/2004_2_1177.pdf; Paramothayan N., Lasserson T., Jones P. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst. Rev. 2005; (2): CD001114. DOI:10.1002/14651858.cd001114.pub2.; ГРЛС. Преднизолон: регистрационное удостоверение. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5bb36449-e307-43d1-ad5a-7171d992c66a&t=; Milman N., Hoffmann A. L., Byg K. E. Sarcoidosis in children. Epidemiology in Danes, clinical features, diagnosis, treatment and prognosis. Acta Paediatrica.1998; 87 (8): 871–878. DOI:10.1080/080352598750013662.; Adami G., Saag K.G. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019; 30 (6): 1145–1156. DOI:10.1007/s00198-019-04906-x.; Scherholz M.L., Schlesinger N., Androulakis I.P. Chronopharmacology of glucocorticoids. Adv. Drug Deliv. Rev. 2019. 151–152; 245–261. DOI:10.1016/j.addr.2019.02.004.; Dinsen S., Baslund B., Klose M. et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur. J. Intern. Med. 2013; 24 (8): 714–720. DOI:10.1016/j.ejim.2013.05.014.; Coker R. K. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs. 2007; 67 (8): 1139–1147. DOI:10.2165/00003495-200767080-00004.; Herlow L.B., Rasmussen N. [Laryngeal sarcoidosis in 13 year-old teenager]. Ugeskr. Laeger. 2010; 172 (45): 3116–3117. Available at: https://ugeskriftet.dk/files/scientific_article_files/2014-04//artikel_8769.pdf (in Danish).; ГРЛС. Метотрексат: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=43da4be2-b2bc-4eaa-8031-aae6250bf870&t=; Cremers J.P., Drent M., Bast A. et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr. Opin. Pulm. Med. 2013; 19 (5): 545–561. DOI:10.1097/mcp.0b013e3283642a7a.; Гаврисюк В., Меренкова Е., Гуменюк Г. и др. Эффективность и безопасность монотерапии метотрексатом у пациентов с саркоидозом легких. Georgian Med. News. 2018; (283): 34–38. Доступно на: https://geomednews.com/s/480918712df344a4a77508d4cd7815ab/files/uploaded/V283_N10_October_2018.pdf?; Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc. Diffuse Lung Dis. 2000; 17 (1): 60–66. Available at: https://read.qxmd.com/read/10746262/methotrexate-is-steroid-sparing-in-acute-sarcoidosis-results-of-a-double-blind-randomized-trial; Визель А.А., Визель И.Ю. Применение метотрексата при саркоидозе (по данным контролируемого проспективного исследования). Клиническая медицина. 2015; 93 (1): 41–46. Доступно на: https://cyberleninka.ru/article/n/primenenie-metotreksata-pri-sarkoidoze-po-dannym-kontroliruemogo-prospektivnogo-issledovaniya/viewer; Gedalia A., Molina J.F., Ellis G.S. Jr. et al. Low-dose methotrexate therapy for childhood sarcoidosis. J. Pediatr. 1997; 130 (1): 25–29. DOI:10.1016/s0022-3476(97)70306-8.; Gedalia A., Khan T.A., Shetty A.K. et al. Childhood sarcoidosis: Louisiana experience. Clin. Rheumatol. 2016; 35 (7): 1879–1884. DOI:10.1007/s10067-015-2870-9.; Birnie D., Beanlands R.S.B., Nery P. et al. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT). Am. Heart J. 2020; 220: 246–252. DOI:10.1016/j.ahj.2019.10.003.; Ning N., Guo H.H., Iagaru A. et al. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J. Card. Fail. 2019; 25 (4): 307–311. DOI:10.1016/j.cardfail.2019.02.018.; Soriano F. G., Caramelli P., Nitrini R., Rocha A.S. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad. Med. J. 1990; 66 (772): 142–143. DOI:10.1136/pgmj.66.772.142.; Judson M. A. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am. J. Med. Sci. 2008; 335 (1): 26–33. DOI:10.1097/maj.0b013e31815d8276.; Vorselaars A.D., Cremers J.P., Grutters J.C., Drent M. Cytotoxic agents in sarcoidosis: which one should we choose? Curr. Opin. Pulm. Med. 2014; 20 (5): 479–487. DOI:10.1097/mcp.0000000000000078.; Ballul T., Borie R., Crestani B. et al. Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs. Int. J. Cardiol. 2019; 276: 208–211. DOI:10.1016/j.ijcard.2018.11.131.; Lewis S.J., Ainslie G.M., Bateman E.D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 1999; 16 (1): 87–92. Available at: https://www.semanticscholar.org/paper/Efficacy-of-azathioprine-as-second-line-treatment-Lewis-Ainslie/f8f6fe3938be432c3d49af53d4d8fcacac308453; Beegle S.H., Barba K., Gobunsuy R., Judson M.A. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des. Devel. Ther. 2013; 7: 325–328. DOI:10.2147/dddt.s31064.; ГРЛС. Азатиоприн: регистрационное удостоверение Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=186056b6-254d-44c1-a1c8-aac7f595a198&t=; El Jammal T., Jamilloux Y., Gerfaud-Valentin M. et al. Refractory sarcoidosis: a review. Ther. Clin. Risk. Manag. 2020; 16: 323–345. DOI:10.2147/TCRM.S192922.; Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2004; 21 (1): 43–48. DOI:10.1007/s11083-004-5178-y.; Raj R., Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc. Diffuse Lung Dis. 2013; 30 (3): 167–176. Available at: https://www.researchgate.net/publication/258957656_Leflunomide-induced_interstitial_lung_disease_a_systematic_review; Bohelay G., Bouaziz J.D., Nunes H. et al. Striking leflunomide efficacy against refractory cutaneous sarcoidosis. J. Am. Acad. Dermatol. 2014; 70 (5): e111–113. DOI:10.1016/j.jaad.2013.10.048.; Sahoo D.H., Bandyopadhyay D., Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur. Respir. J. 2011; 38 (5): 1145–1150. DOI:10.1183/09031936.00195010.; ГРЛС. Арресто: регистрационное удостоверение Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=46c1c8dd-0c2e-48b0-bf3e-be5a206a1238&t=; Hamzeh N., Voelker A., Forssen A. et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir. Med. 2014; 108 (11): 1663–1669. DOI:10.1016/j.rmed.2014.09.013.; Мухин Н.А., ред. Саркоидоз: клинические рекомендации. М.: ИМА-ПРЕСС; 2009.; Kikuchi N., Nunoda S., Serizawa N. et al. Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis. J. Cardiol. Cases. 2016; 13 (4): 125–128. DOI:10.1016/j.jccase.2015.12.008.; ГРЛС. Фломирен: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9fd35729-ab22-4b2c-a80d-41619164b8b2&t=; Moudgil A., Przygodzki R. M., Kher K. K. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr. Nephrol. 2006; 21 (2): 281–285. DOI:10.1007/s00467-005-2086-3.; ГРЛС. Эндоксан: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cc8c311d-6bae-4a30-b1d2-f4e74e5f3644&t; Rabinowitz M.P., Murchison A.P. Orbital sarcoidosis treated with hydroxychloroquine. Orbit. 2011; 30 (1): 13–15. DOI:10.3109/01676830.2010.524268.; Kiedrowicz M., Kacalak-Rzepka A., Bielecka-Grzela S., Maleszka R. [Antimalarial drugs in contemporary dermatologic therapy]. Ann. Acad. Med. Stetin. 2011; 57 (1): 38–44. Available at: https://www.researchgate.net/publication/224975968_Antimalarial_drugs_in_contemporary_dermatologic_therapy; ГРЛС. Плаквенил: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=92eff6a5-c78c-4d28-910b-cdcc78986307&t=; Baltzan M., Mehta S., Kirkham T.H., Cosio M.G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 1999; 160 (1): 192–197. DOI:10.1164/ajrccm.160.1.9809024.; Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. 1997; 155 (5): 1665–1669. DOI:10.1164/ajrccm.155.5.9154873.; Park M.K., Fontana Jr., Babaali H. et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26 (2): 121–131. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946799/; Popova E.N., Bolevich S.B., Fomin V.V. et al. Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite). Eur. Respir. J. 2006; 28 (Suppl. 50): 2491. Available at: https://www.ers-education.org/lr/show-details/?idP=7643; Бородина Г.Л. Антицитокиновая терапия пентоксифиллином в виде монотерапии и в сочетании с глюкокортикостероидами при саркоидозе органов дыхания. Туберкулз и болезни легких. 2013; (8): 15–20. Доступно на: https://www.elibrary.ru/download/elibrary_20658497_99153726.pdf; Костина З.И., Браженко Н.А., Насорина Р.Н. Отдаленные результаты наблюдения за леченными больными саркоидозом органов дыхания. Проблемы туберкулеза. 1995; (3): 34–37.; Зубович Г.Л., Абрамовская А.К., Камышников В.С. и др. Показатели гомеостаза у больных саркоидозом органов дыхания. Пульмонология. 1996; (2): 50–54. Доступно на: https://journal.pulmonology.ru/pulm/article/view/3430/2817; Drent M., Cremers J.P., Jansen T.L., Baughman R.P. Practical eminence and experiencebased recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31 (2): 91–107. Available at: https://www.wasog.org/dynamic/media/78/documents/2014_Drent_et_al_Sarcoidosis_anti-TNF.pdf; Simonini G., Taddio A., Cattalini M. et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. (Hoboken). 2011; 63 (4): 612–618. DOI:10.1002/acr.20404.; Orandi A.B., Eutsler E., Ferguson C. et al. Sarcoidosis presenting as granulomatous myositis in a 16-year-old adolescent. Pediatr. Rheumatol. Online J. 2016; 14 (1): 59. DOI:10.1186/s12969-016-0121-5.; Judson M.A., Baughman R.P., Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur. Respir. J. 2014; 44 (5): 1296–1307. DOI:10.1183/09031936.00000914.; Utz J.P., Limper A.H., Kalra S. et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003; 124 (1): 177–185. DOI:10.1378/chest.124.1.177.; Majjad A., Bezza A., Biyi A. et al. Pulmonary sarcoidosis following etanercept treatment for ankylosing spondylitis: a case report and review of the literature. Case Rep. Rheumatol. 2018; 2018: 9867248. DOI:10.1155/2018/9867248.; Kim T.K., Kang S.H., Moon H.S. et al. Pulmonary sarcoidosis that developed during the treatment of a patient with Crohn disease by using infliximab. Ann. Coloproctol. 2017; 33 (2): 74–77. DOI:10.3393/ac.2017.33.2.74.; Инструкция по медицинскому применению лекарственного препарата Варгатеф®. Дата утверждения МЗ РФ 10.07.20. Доступно на: https://www.boehringer-ingelheim.ru/sites/ru/files/files/vargatef_pil_10-07-2020.pdf; Flaherty K.R., Wells A. U., Cottin V. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019; 381 (18): 1718–1727. DOI:10.1056/NEJMoa1908681.; Шмелёв Е.И. Саркоидоз. Пульмонология и аллергология. 2004; 13 (2): 3–10. Доступно на: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/ap_2_2004_03.pdf; Романов В.В. Экстракорпоральные методы в лечении больных саркоидозом. Проблемы туберкулеза. 2001; (3): 45–49.; Баранова О.П., Бакланова О.Э., Войнов В.А., Карчевский К.С. Применение плазмафереза в комплексном лечении больных саркоидозом легких. В кн.: Чучалин А.Г., ред. XIX Национальный Конгресс по болезням органов дыхания: cборник трудов. М.: ДизайнПресс, 2009: 215.; Смелая Т.В., Сивцевич Н.Н., Жолобов И.М. Экстракорпоральная фармакотерапия при лечении пациентов с различной нозологией. Медицинский вестник МВД. 2017; 91 (6): 44–50.; Taimeh Z., Hertz M.I., Shumway S., Pritzker M. Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. Thorax. 2016; 71 (4): 378–379. DOI:10.1136/thorax-jnl-2015-207497.; Salamo O., Roghaee S., Schweitzer M.D. et al. White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients. Sci. Rep. 2018; 8 (1): 6968. DOI:10.1038/s41598-018-25144-x.; Meyer K.C. Lung transplantation for pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2019; 36 (2): 92–107. DOI:10.36141/svdld.v36i2.7163.; Rosenthal D.G., Anderson M.E., Petek B.J. et al. Invasive hemodynamics and rejection rates in patients with cardiac sarcoidosis after heart transplantation. Can. J. Cardiol. 2018; 34 (8): 978–982. DOI:10.1016/j.cjca.2018.03.021.; Sawahata M., Shijubo N., Johkoh T. et al. Progression of central-peripheral band and traction bronchiectasis clusters leading to chronic respiratory failure in a patient with fibrotic pulmonary sarcoidosis. Intern. Med. 2021; 60 (1): 111–116. DOI:10.2169/internalmedicine.4862-20.; Faverio P., De Giacomi F., Sardella L. et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm. Med. 2018; 18 (1): 1–13. DOI:10.1186/s12890-018-0643-3.; Авдеев С.Н. Легочная гипертензия при саркоидозе. Пульмонология. 2016; 26 (6): 725–735. DOI:10.18093/0869-0189-2016-26-6-725-735.; Parikh K.S., Dahhan T., Nicholl L. et al. Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension. Sci. Rep. 2019; 9 (1): 4061. DOI:10.1038/s41598-019-40030-w.; Corte T.J., Wells A.U., Nicholson A.G. et al. Pulmonary hypertension in sarcoidosis: a review. Respirology. 2011; 16 (1): 69–77. DOI:10.1111/j.1440-1843.2010.01872.x.; Бородина Г.Л. Разработка программы медицинской реабилитации пациентов с саркоидозом органов дыхания и оценка ее эффективности. Вестник современной клинической медицины. 2012; 5 (1): 11–20. Доступно на: http://vskmjournal.org/images/Files/Issues_Archive/2012/Issue_1/VSKM_2012_N_1_p11-20.pdf; Niedoszytko P. [Rehabilitation of patients with sarcoidosis]. Pol. Merkur. Lekarski. 2018; 44 (261): 150–151. Available at: https://www.researchgate.net/publication/324129986_Rehabilitation_of_patients_with_sarcoidosis; Черников А.Ю. Об эффективности медицинской реабилитации больных саркоидозом в общей лечебной сети. Здравоохранение Российской Федерации. 2008; (4): 36–39.; Черников А.Ю., Дауров Б.И. Эффективность диспансеризации больных саркоидозом в условиях общей лечебной сети. Проблемы туберкулtза и болезней лtгких. 2007; 84 (8): 3–5.; Гармаш Ю.Ю. Основные принципы наблюдения за больными саркоидозом. Российский медицинский журнал. 2009; (1): 22–23.; https://journal.pulmonology.ru/pulm/article/view/4155

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4155
https://doi.org/10.18093/0869-0189-2022-32-6-806-833

المؤلفون: S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, M. M. Ilkovich, E. A. Kogan, Z. M. Merzhoeva, D. V. Petrov, M. V. Samsonova, S. A. Terpigorev, N. V. Trushenko, I. N. Trofimenko, I. E. Tyurin, A. L. Chernyaev, B. A. Chernyak, A. V. Chernyak, S. Yu. Chikina, A. G. Chuchalin, E. I. Shmelev, С. Н. Авдеев, З. Р. Айсанов, А. С. Белевский, М. М. Илькович, Е. А. Коган, З. М. Мержоева, Д. В. Петров, М. В. Самсонова, С. А. Терпигорев, Н. В. Трушенко, И. Н. Трофименко, И. Е. Тюрин, А. Л. Черняев, Б. А. Черняк, А. В. Черняк, С. Ю. Чикина, А. Г. Чучалин, Е. И. Шмелев

المصدر: PULMONOLOGIYA; Том 32, № 3 (2022): Спецвыпуск; 473-495 ; Пульмонология; Том 32, № 3 (2022): Спецвыпуск; 473-495 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: антифибротическая терапия, interstitial lung disease, usual interstitial pneumonia, antifibrotic therapy, интерстициальные заболевания легких, обычная интерстициальная пневмония

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4111/3417; Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788–824. DOI:10.1164/rccm.2009-040GL.; Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS/ERS/ JRS/ALAT clinical practice guideline: treatment of Idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192 (2): e3–19. DOI:10.1164/rccm.201506-1063ST.; Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733–748. DOI:10.1164/rccm.201308-1483ST.; Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79 (1): 149–154. DOI:10.1086/504639.; Allen R.J., Porte J., Braybrooke R. et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir. Med. 2017; 5 (11): 869–880. DOI:10.1016/S2213-2600(17)30387-9.; Авдеев С.Н. Идиопатический фиброз легких: новая парадигма. Терапевтический архив. 2017; 89 (1): 112–122. DOI:10.17116/terarkh2017891112-122; Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc. Am. Thorac. Soc. 2006; 3 (4): 293–298. DOI:10.1513/pats.200512-131TK.; Bedard Methot D., Leblanc E., Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. 2019; 155 (1): 33–43. DOI:10.1016/j.chest.2018.07.038.; Garcıa-Sancho Figueroa M.C., Carrillo G., Pérez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population: a case-control study. Respir. Med. 2010; 104 (2): 305–309. DOI:10.1016/j.rmed.2009.08.013.; Oldham J.M., Kumar D., Lee C. et al. Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis. Chest. 2015; 148 (3): 692–700. DOI:10.1378/chest.14-2714.; Stock C.J., Sato H., Fonseca C. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013; 68 (5): 436–441. DOI:10.1136/thoraxjnl-2012-201786.; El-Chemaly S., Ziegler S.G., Calado R.T. et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest. 2011; 139 (5): 1203–1209. DOI:10.1378/chest.10-2048.; Tsang A.R., Wyatt H.D., Ting N.S.Y., Beattie T.L. hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell. 2012; 11 (3): 482–490. DOI:10.1111/j.1474-9726.2012.00810.x.; Fukuhara A., Tanino Y., Ishii T., et al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur. Respir. J. 2013; 42 (6): 1757–1759. DOI:10.1183/09031936.00149113.; Kropski J.A., Mitchell D.B., Markin C. et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest. 2014; 146 (1): e1–7. DOI:10.1378/chest.13-2224.; Alder J.K., Stanley S.E., Wagner C.L. et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015; 147 (5): 1361–1368. DOI:10.1378/chest.14-1947.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза: Федеральные клинические рекомендации. Пульмонология. 2016; 26 (4): 399–419. DOI:10.18093/0869-0189-2016-26-4-399-419.; Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI:10.1016/S2213-2600(14)70101-8.; Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174 (7): 810–816. DOI:10.1164/rccm.200602-163OC.; Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150 (4): 967–972. DOI:10.1164/ajrccm.150.4.7921471.; Nalysnyk L., Cid-Ruzafa J., Rotella P., Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21 (126): 355–361. DOI:10.1183/09059180.00002512.; Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine. 2015; 13: 237. DOI:10.1186/s12916-015-0495-0.; Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44–68. DOI:10.1164/rccm.201807-1255ST.; Lynch D.A., Sverzellati N., Travis W.D. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir. Med. 2018; 6 (2): 138–153. DOI:10.1016/S2213-2600(17)30433-2.; George R.B., Light R.W., Mattay M.A., Mattay R.A., eds. Chest Medicine: Essentials of Pulmonary and Critical Care Medicine. 5th edn. Philadelphia: Wolter Kluwers/Lippincott Williams & Wilkins; 2005.; Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis: An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI:10.1164/rccm.201604-0801CI.; Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001; 345 (7): 517–525. DOI:10.1056/NEJMra003200.; King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164 (7): 1171–1181. DOI:10.1164/ajrccm.164.7.2003140.; Авдеев С.Н. Обострение идиопатического легочного фиброза. Пульмонология. 2018; 28 (4): 469–482. DOI:10.18093/0869-0189-2018-28-4-469-482.; Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22 (5): 821–826. DOI:10.1183/09031936.03.00022703.; Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27 (1): 143–150. DOI:10.1183/09031936.06.00114004.; Rajala K., Lehto J.T., Sutinen E. et al. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017; 3 (4): 00084- 2017. DOI:10.1183/23120541.00084-2017.; Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156 (10): 684–691. DOI:10.7326/0003-4819-156-10-201205150-00004.; Sgalla G., Walsh S.L.F., Sverzellati N. et al. “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulm. Med. 2018; 18 (1): 103. DOI:10.1186/s12890-018-0670-0.; Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 538–542. DOI:10.1164/rccm.200211-1311OC.; Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167 (7): 962–969. DOI:10.1164/rccm.2111053.; Mathieson J.R., Mayo J.R., Staples C.A., Muller N.L. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology. 1989; 171 (1): 111–116. DOI:10.1148/radiology.171.1.2928513.; Remy-Jardin M., Campistron P., Amara A. et al. Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease. J. Comput. Assist. Tomogr. 2003; 27 (2): 266–273. DOI:10.1097/00004728-200303000-00028.; Bankier A.A., O’Donnell C.R., Boiselle P.M. Quality initiatives. Respiratory instructions for CT examinations of the lungs: a handson guide. Radiographics. 2008; 28 (4): 919–931. DOI:10.1148/rg.284085035.; Kim M., Lee S.M., Song J.W. et al. Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern. Eur. J. Radiol. 2017; 91: 66–70. DOI:10.1016/j.ejrad.2017.03.018.; Gotway M.B., Lee E.S., Reddy G.P. et al. Low-dose, dynamic, expiratory thin-section CT of the lungs using a spiral CT scanner. J. Thorac. Imaging. 2000; 15 (3): 168–172. DOI:10.1097/00005382-200007000-00003.; Lynch D.A., Godwin J.D., Safrin S. et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005; 172 (4): 488–493. DOI:10.1164/rccm.200412-1756OC.; Remy-Jardin M., Giraud F., Remy J. et al. Importance of groundglass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology. 1993; 189 (3): 693–698. DOI:10.1148/radiology.189.3.8234692.; Silva C.I., Müller N.L., Lynch D.A. et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008; 246 (1): 288–297. DOI:10.1148/radiol.2453061881.; Raghu G., Mageto Y.N., Lockhart D. et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest. 1999; 116 (5): 1168–1174. DOI:10.1378/chest.116.5.1168.; Chung J.H., Chawla A., Peljto A.L. et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest. 2015; 147 (2): 450–459. DOI:10.1378/chest.14-0976.; Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26 (4): 586–593. DOI:10.1183/09031936.05.00021005.; Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186–196. DOI:10.1183/09031936.00217614.; Akagi T., Matsumoto T., Harada T. et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir. Med. 2009; 103 (8): 1209–1215. DOI:10.1016/j.rmed.2009.02.001.; Enright P.L. The Six-Minute Walk Test. Respir. Care. 2003; 48 (8): 783–785. Available at: http://rc.rcjournal.com/content/48/8/783.full.pdf; Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168 (9): 1084–1090. DOI:10.1164/rccm.200302-219OC.; du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011; 184 (12): 1382–1389. DOI:10.1164/rccm.201105-0840OC.; Caminati A., Bianchi A., Cassandro R. et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir. Med. 2009; 103 (1): 117–123. DOI:10.1016/j.rmed.2008.07.022.; Lederer D.J., Arcasoy S.M., Wilt J.S. et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174 (6): 659–664. DOI:10.1164/rccm.200604-520OC.; Dowman L., Hill C.J., Holland A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst. Rev. 2014; (10): CD006322. DOI:10.1002/14651858.CD006322.pub3.; Mapel D.W., Samet J.M., Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: Past, present, and future. Chest. 1996; 110 (4): 1058–1067. DOI:10.1378/chest.110.4.1058.; Hanson D., Winterbauer R.H., Kirtland S.H., Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995; 108 (2): 305–310. DOI:10.1378/chest.108.2.305.; Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161 (4, Pt 1): 1172–1178. DOI:10.1164/ajrccm.161.4.9907002.; Raghu G., Depaso W.J., Cain K. et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991; 144 (2): 291–296. DOI:10.1164/ajrccm/144.2.291.; Flaherty K.R., Toews G.B., Lynch J.P. et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110 (4): 278–282. DOI:10.1016/s0002-9343(00)00711-7.; Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2093–2101. DOI:10.1056/NEJMoa1401739.; Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156 (6): 1897–1901. DOI:10.1164/ajrccm.156.6.9706065.; Tomioka H., Kuwata Y., Imanaka K. et al. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology. 2005; 10 (4): 449–455. DOI:10.1111/j.1440-1843.2005.00725.x.; Oldham J.M., Ma S.F., Martinez F.J. et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192 (12): 1475–1482. DOI:10.1164/rccm.201505-1010OC.; Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242. DOI:10.1056/NEJMoa042976.; Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366 (21): 1968–1977. DOI:10.1056/NEJMoa1113354.; Raghu G., Behr J., Brown K.K. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann. Intern. Med. 2013; 158 (9): 641–649. DOI:10.7326/0003-4819-158-9-201305070-00003.; Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186 (1): 88–95. DOI:10.1164/rccm.201202-0314OC.; Lee J.S., Collard H.R., Anstrom K.J. et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 2013; 1 (5): 369–376. DOI:10.1016/S2213-2600(13)70105-X.; Tran T., Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur. Respir. J. 2018; 51 (6): 1800376. DOI:10.1183/13993003.00376-2018.; Di Martino E., Provenzani A., Vitulo P., Polidori P. Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Ann. Pharmacother. 2021; 55 (6): 723–731. DOI:10.1177/1060028020964451.; Lancaster L., Crestani B., Hernandez P. et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir. Res. 2019; 6 (1): e000397. DOI:10.1136/bmjresp-2018-000397.; Skandamis A., Kani C., Markantonis S.L., Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J. Drug Assess. 2019; 8 (1): 55–61. DOI:10.1080/21556660.2019.1597726.; Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365 (12): 1079–1087. DOI:10.1056/NEJMoa1103690.; Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI:10.1056/NEJMoa1402584.; Crestani B., Huggins J.T., Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir. Med. 2019; 7 (1): 60–68. DOI:10.1016/S2213-2600(18)30339-4.; Richeldi L., Cottin V., du Bois R.M. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir. Med. 2016; 113: 74–79. DOI:10.1016/j.rmed.2016.02.001.; Авдеев С.Н. Новые возможности терапии идиопатического легочного фиброза. Пульмонология. 2017; 27 (4): 502–514. DOI:10.18093/0869-0189-2017-27-4-502-514.; Авдеев С.Н., Трушенко Н.В. Антифибротическая терапия идиопатического легочного фиброза: соотношение эффективности и безопасности. Медицинский совет. 2018; (15): 131–136. DOI:10.21518/2079-701X-2018-15-131-136.; Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377 (9779): 1760–1769. DOI:10.1016/S0140-6736(11)60405-4.; King T.E., Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2083–2092. DOI:10.1056/NEJMoa1402582.; Nathan S.D., Albera C., Bradford W.Z. et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir. Med. 2017; 5 (1): 33–41. DOI:10.1016/S2213-2600(16)30326-5.; Авдеев С.Н., Чикина С.Ю., Нагаткина О.В. Идиопатический легочный фиброз: новые международные клинические рекомендации. Пульмонология. 2019; 29 (5): 525–552. DOI:10.18093/0869-0189-2019-29-5-525-552.; Richeldi L., Cottin V., Flaherty K.R. et al. Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir. Med. 2014; 108 (7): 1023–1030. DOI:10.1016/j.rmed.2014.04.011.; Birring S.S., Kavanagh J.E., Irwin R.S. et al. Treatment of interstitial lung disease associated cough: CHEST guideline and expert panel report. Chest. 2018; 154 (4): 904–917. DOI:10.1016/j.chest.2018.06.038.; Nathan S.D., Costabel U., Albera C. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir. Med. 2019; 153: 44–51. DOI:10.1016/j.rmed.2019.04.016.; Polke M, Kondoh Y, Wijsenbeek M. et al. Management of acute exacerbation of idiopathic pulmonary fibrosis in specialised and non-specialised ILD centres around the world. Front. Med. (Lausanne). 2021; 8: 699644. DOI:10.3389/fmed.2021.699644.; Kreuter M., Polke M., Walsh S.L.F. et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur. Respir. J. 2020; 55 (4): 1901760. DOI:10.1183/13993003.01760-2019.; Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal oxygen therapy trial group. Ann. Intern. Med. 1980; 93 (3): 391–398. DOI:10.7326/0003-4819-93-3-391.; Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981; 317 (8222): 681–686. DOI:10.1016/S0140-6736(81)91970-X.; Faverio P., De Giacomi F., Sardella L. et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm. Med. 2018; 18 (1): 70. DOI:10.1186/s12890-018-0643-3.; Dreher M., Ekkernkamp E., Schmoor C. et al. Pulmonary rehabilitation and noninvasive ventilation in patients with hypercapnic interstitial lung disease. Respiration. 2015; 89 (3): 208–213. DOI:10.1159/000369862.; Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120 (1): 213–219. DOI:10.1378/chest.120.1.213.; Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can. Respir. J. 2004; 11 (2): 117–122. DOI:10.1155/2004/379723.; Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010; 79 (3): 209–215. DOI:10.1159/000225932.; Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126 (2): 469–475. DOI:10.1016/s0022-5223(03)00600-7.; Hanada M., Kasawara K.T., Mathur S. et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J. Thorac. Dis. 2020; 12 (3): 1041–1055. DOI:10.21037/jtd.2019.12.27.; King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127 (1): 171–177. DOI:10.1378/chest.127.1.171.; Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35 (4): 830–836. DOI:10.1183/09031936.00155108.; Zieliński M., Sitek P., Ziora D. Idiopathic pulmonary fibrosis coexisting with lung cancer – a review. Adv. Respir. Med. 2018; 86 (6): 319–326. DOI:10.5603/ARM.a2018.0052.; Karampitsakos T., Tzilas V., Tringidou R. et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2017; 45: 1–10. DOI:10.1016/j.pupt.2017.03.016.; Costabel U., Crestani B., Wells A., eds. Idiopathic Pulmonary Fibrosis: ERS Monograph. Plymouth: Latimer Trend and Company Limited; 2016. DOI:10.1183/2312508X.erm7116.; Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360 (9337): 895–900. DOI:10.1016/S0140-6736(02)11024-5.; Madden B.P., Allenby M., Loke T.K., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44 (5): 372–376. DOI:10.1016/j.vph.2006.01.013.; Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131 (3): 897–899. DOI:10.1378/chest.06-2101.; Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160 (2): 600–607. DOI:10.1164/ajrccm.160.2.9810008.; Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med. 2008; 102 (7): 1015–1020. DOI:10.1016/j.rmed.2008.02.002.; Fulton B.G., Ryerson C.J. Managing comorbidities in idiopathic pulmonary fibrosis. Int. J. Gen. Med. 2015: 8: 309–318. DOI:10.2147/IJGM.S74880.; Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006; 129 (3): 794–800. DOI:10.1378/chest.129.3.794.; Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131 (2): 438–446. DOI:10.1016/j.jtcvs.2005.10.014.; Lee J.S., Ryu J.H., Elicker B.M. et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184 (12): 1390–1394. DOI:10.1164/rccm.201101-0138OC.; Savarino E., Bazzica M., Zentilin P. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 2009; 179 (5): 408–413. DOI:10.1164/rccm.200808-1359OC.; Cano-Jiménez E., Hernández González F., Peloche G.B. Comorbidities and complications in idiopathic pulmonary fibrosis. Med. Sci. 2018; 6 (3): 71. DOI:10.3390/medsci6030071.; Kreuter M., Brunnemer E., Ehlers-Tenenbaum S. et al. Other comorbidities. In: Costabel U., Crestani B., Wells A., eds. Idiopathic pulmonary fibrosis: ERS Monograph. Plymouth: Latimer Trend and Company Limited; 2016: 186–195. DOI:10.1183/2312508X.erm7116.; Mahler D.A., Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93 (3): 580–586. DOI:10.1378/chest.93.3.580.; https://journal.pulmonology.ru/pulm/article/view/4111

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4111
https://doi.org/10.18093/0869-0189-2022-32-3-473-495

المؤلفون: S. N. Avdeev, S. Yu. Chikina, I. E. Tyurin, A. S. Belevskiy, S. A. Terpigorev, L. P. Anan’yeva, A. A. Vizel’, M. V. Boldina, I. V. Demko, I. V. Leshchenko, I. N. Trofimenko, M. F. Kinyaykin, I. E. Stepanyan, A. S. Zaytseva, D. V. Petrov, С. Н. Авдеев, С. Ю. Чикина, И. Е. Тюрин, А. С. Белевский, С. А. Терпигорев, Л. П. Ананьева, А. А. Визель, М. В. Болдина, И. В. Демко, И. В. Лещенко, И. Н. Трофименко, M. Ф. Киняйкин, И. Э. Степанян, А. С. Зайцева, Д. В. Петров

المساهمون: This publication is supported by Boehringer Ingelheim LLC. The company is not responsible for the content of this article, Статья опубликована при финансовой поддержке ООО Берингер Ингельхейм. ООО Берингер Ингельхейм не несет ответственности за содержание статьи

المصدر: PULMONOLOGIYA; Том 31, № 4 (2021); 505-510 ; Пульмонология; Том 31, № 4 (2021); 505-510 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: нинтеданиб, progressive fibrosing phenotype, nintedanib, antifibrotic, algorithm, фиброзирующие интерстициальные заболевания легких, прогрессирующий фенотип, антифибротическая терапия, алгоритм

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2413/1864; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165 (2): 277–304. DOI:10.1164/ajrccm.165.; ats01. 2. George P.M., Spagnolo P., Kreuter M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 2020; 8 (9): 925–934. DOI:10.1016/S2213-2600(20)30355-6.; Wijsenbeek M., Cottin V. Spectrum of fibrotic lung diseases. N. Engl. J. Med. 2020; 383 (10): 958–968. DOI:10.1056/NEJMra2005230.; De Sadeleer L.J., Hermans F., De Dycker E. et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: A single-centre cohort study. J. Clin. Med. 2019; 8 (1): 14. DOI:10.3390/jcm8010014.; Fischer A., Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin. Rheumatol. 2019; 38 (10): 2673–2681. DOI:10.1007/s10067-019-04720-0.; Brown K.K., Martinez F.J., Walsh S.L.F. et al. The natural history of progressive fibrosing interstitial lung diseases. Eur. Respir. J. 2020; 55 (6): 2000085. DOI:10.1183/13993003.00085-2020.; Kolb M., Richeldi L., Behr J. et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017; 72 (4): 340–346. DOI:10.1136/thoraxjnl-2016-208710.; Distler O., Highland K.B., Gahlemann M. et al. Nintedanib for systemic sclerosis – associated interstitial lung disease. N. Engl. J. Med. 2019; 380 (26): 2518–2528. DOI:10.1056/NEJMoa1903076.; Flaherty K.R., Wells A.U., Cottin V. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019; 381 (18): 1718–1727. DOI:10.1056/NEJMoa1908681.; Российское респираторное общество. Идиопатический легочный фиброз: Федеральные клинические рекомендации. 2016. Доступно на: https://www.volgmed.ru/uploads/files/2018-10/90708-idiopaticheskij_legochnyj_fibroz_2016.pdf [Дата обращения: 21.06.21].; https://journal.pulmonology.ru/pulm/article/view/2413

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2413
https://doi.org/10.18093/0869-0189-2021-31-4-505-510

المؤلفون: A. V. Chernyak, S. N. Avdeev, A. S. Belevskiy, I. E. Tyurin, S. Yu. Chikina, Z. M. Merzhoeva, S. A. Terpigorev, M. Yu. Brovko, G. V. Neklyudova, N. Yu. Kravchenko, А. В. Черняк, С. Н. Авдеев, А. С. Белевский, И. Е. Тюрин, С. Ю. Чикина, З. М. Мержоева, С. А. Терпигорев, М. Ю. Бровко, Г. В. Неклюдова, Н. Ю. Кравченко

المصدر: PULMONOLOGIYA; Том 30, № 1 (2020); 31-41 ; Пульмонология; Том 30, № 1 (2020); 31-41 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2020-30-1

مصطلحات موضوعية: одышка, pulmonary function test, tolerance to the physical activity, shortness of breath, функция внешнего дыхания, толерантность к физической нагрузке

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1278/980; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016; 26 (4): 399–419. DOI:10.18093/0869-0189-2016-26-4-399-419.; Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/ JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44–68. DOI:10.1164/rccm.201807-1255ST.; Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134 (2): 136–151. DOI:10.7326/0003-4819-134-2-200101160-00015.; Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med. 2013; 19 (5): 460–465. DOI:10.1097/MCP.0b013e328363f4b7.; Shimbori C., Gauldie J., Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr. Opin. Pulm. Med. 2013; 19 (5): 446–452. DOI:10.1097/MCP.0b013e328363f4de.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; 6: 11–23.; Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338. DOI:10.1183/09031936.05.00034805.; Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26 (3): 511–522. DOI:10.1183/09031936.05.00035005.; Macintyre N., Crapo R.O., Viegi G. et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005; 26 (4): 720–735. DOI:10.1183/09031936.05.00034905.; Holland A.E., Spruit M.A., Troosters T. et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur. Respir. J. 2014; 44 (6): 1428–1446. DOI:10.1183/09031936.00150314.; Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168 (9): 1084–1090. DOI:10.1164/rccm.200302-219OC.; Enright P.L., Sherrill D.L. Reference equations for the sixminute walk in healthy adults. Am. J. Respir. Crit. Care Med. 1998; 158 (5, Pt 1): 1384–1387. DOI:10.1164/ajrccm.158.5.9710086.; Jegal Y., Kim D.S., Shim T.S. et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171 (6): 639–644. DOI:10.1164/rccm.200403-331OC.; Flaherty K.R., Mumford J.A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 543–548. DOI:10.1164/rccm.200209-1112OC.; Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 538–542. DOI:10.1164/rccm.200211-1311OC.; Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157 (1): 199–203. DOI:10.1164/ajrccm.157.1.9704130.; Daniil Z.D., Gilchrist F.C., Nicholson A.G. et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 899–905. DOI:10.1164/ajrccm.160.3.9903021.; Latsi P.I., du Bois R.M., Nicholson A.G. et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 531–537. DOI:10.1164/rccm.200210-1245OC.; Hyldgaard C., Hilberg O., Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014; 108 (4): 647–653. DOI:10.1016/j.rmed.2014.01.008.; Kaunisto J., Kelloniemi K., Sutinen E. et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm. Med. 2015; 15: 92. DOI:10.1186/s12890-015-0074-3.; Doubková M., Švancara J., Svoboda M. et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin. Respir. J. 2018; 12 (4): 1526–1535. DOI:10.1111/crj.12700.; Wuyts W.A., Dahlqvist C., Slabbynck H. et al. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Br. Med. J. Open Respir. Res. 2018; 5 (1): e000331. DOI:10.1136/bmjresp-2018-000331.; Guler S., Zumstein P., Berezowska S. et al. Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Med. Wkly. 2018; 148: w14577. DOI:10.4414/smw.2018.14577.; Jo H.E., Glaspole I., Grainge C. et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur. Respir. J. 2017; 49 (2): pii: 1601592. DOI:10.1183/13993003.01592-2016.; Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186–196. DOI:10.1183/09031936.00217614.; Ferrara G., Carlson L., Palm A. et al. Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. Eur. Clin. Respir. J. 2016; 3 (1): 31090. DOI:10.3402/ecrj.v3.31090.; Jankowich M.D., Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung. 2010; 188 (5): 365–373. DOI:10.1007/s00408-010-9251-6.; Wells A.U., King A.D., Rubens M.B. et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am. J. Respir. Crit. Care Med. 1997; 155 (4): 1367–1375. DOI:10.1164/ajrccm.155.4.9105081.; Xaubet A., Agusti C., Luburich P. et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158 (2): 431–436. DOI:10.1164/ajrccm.158.2.9709008.; Isaac B.T., Thangakunam B., Cherian R.A., Christopher D.J. The correlation of symptoms, pulmonary function tests and exercise testing with high-resolution computed tomography in patients with idiopathic interstitial pneumonia in a tertiary care hospital in South India. Lung India. 2015; 32 (6): 584–588. DOI:10.4103/0970-2113.168131.; https://journal.pulmonology.ru/pulm/article/view/1278

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1278
https://doi.org/10.18093/0869-0189-2020-30-1-31-41

المؤلفون: S. N. Avdeev, L. P. Ananyeva, E. V. Zhilyaev, E. V. Zonova, A. A. Klimenko, O. A. Koneva, A. M. Lila, E. S. Pershina, A. A. Stremoukhov, S. A. Terpigorev, I. E. Tyurin, N. A. Shostak, С. Н. Авдеев, Л. П. Ананьева, Е. В. Жиляев, Е. В. Зонова, А. А. Клименко, О. А. Конева, А. М. Лила, Е. С. Першина, А. А. Стремоухов, С. А. Терпигорев, И. Е. Тюрин, Н. А. Шостак

المساهمون: Статья спонсируется компанией ООО «Берингер Ингельхайм».

المصدر: Modern Rheumatology Journal; Том 14, № 1 (2020); 125-128 ; Современная ревматология; Том 14, № 1 (2020); 125-128 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-1

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1003/962; Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-55. doi:10.1136/annrheumdis-2013-204424; Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66: 754-63. doi:10.1136/ard.2006.062901; Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894. doi:10.1371/journal.pone.0163894; Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46:115-23. doi:10.1016/j.semarthrit.2016.02.005; Fischer A, Zimovetz E, Ling C, et al. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16:1147-54. doi:10.1016/j.autrev.2017.09.010; Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76: 1897-905. doi:10.1136/annrheumdis-2017- 211448; Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655-66. doi:10.1056/NEJMoa055120; Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-19. doi:10.1016/S2213-2600(16)30152-7; Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45:1434-45. doi:10.1183/09031936.00174914; Чучалин АГ, Авдеев СН, Айсанов ЗР и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016;26(4):399-419. [Chuchalin AG, Avdeev SN, Aysanov ZR, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal clinical guidelines. Pul'monologiya. 2016;26(4):399-419 (In Russ.)].; Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-87. doi:10.1056/NEJMoa1103690; Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82. doi:10.1056/NEJMoa1402584; Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol. 1995; 105:128-32. doi:10.1111/1523-1747.ep12313452; Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783-94. doi:10.1002/art.30159; Lam AP, Flozak AS, Russell S, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45:915-22. doi:10.1165/rcmb.2010-0113OC; Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76: 1941-8. doi:10.1136/annrheumdis-2016- 210823; Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-28. doi:10.1056/NEJM oa1903076; Flaherty KR, Wells AU, Vincent Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381:1718-27. doi:10.1056/NEJMoa1908681; https://mrj.ima-press.net/mrj/article/view/1003

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1003
https://doi.org/10.14412/1996-7012-2020-1-125-128

المؤلفون: S. A. Terpigorev, A. M. Nikishenkov, S. G. Nikishenkova, С. А. Терпигорев, А. М. Никишенков, С. А. Никишенкова

المصدر: PULMONOLOGIYA; Том 29, № 4 (2019); 486-492 ; Пульмонология; Том 29, № 4 (2019); 486-492 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2019-29-4

مصطلحات موضوعية: варианты течения, nintedanib, prognosis, treatment, нинтеданиб, лечение, прогноз

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1202/944; Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788–824. DOI:10.1164/rccm.2009-040GL.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза: Федеральные клинические рекомендации. Пульмонология. 2016; 26 (4): 399–419. DOI:10.18093/0869-0189-2016-26-4-399-419.; Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733–748. DOI:10.1164/rccm.201308-1483ST.; Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI:10.1016/S2213-2600(14)70101-8.; Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44–e68. DOI:10.1164/rccm.201807-1255ST.; Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI:10.1164/rccm.201604-0801CI.; Kondoh Y., Cottin V., Brown K.K. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2017; 26 (145): pii: 170050. DOI:10.1183/16000617.0050-2017.; Lancaster L., Crestani B., Hernandez P. et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir. Res. 2019; 6 (1): e000397. DOI:10.1136/ bmjresp-2018-000397.; Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI:10.1056/NEJMoa1402584.; Kreuter M., Swigris J., Pittrow D. et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir. Res. 2019; 20 (1): 59. DOI:10.1186/s12931-019-1020-3.; Crestani B., Huggins J.T., Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir. Med. 2019; 7 (1): 60–68. DOI:10.1016/S2213-2600(18)30339-4.; Fabrellas F.E., Sanchez P.R., Abad S.C., Juan J.G. Prognosis and follow-up of idiopathic pulmonary fibrosis. Med. Sci. (Basel). 2018; 6 (2): pii: 51. DOI:10.3390/medsci6020051.; https://journal.pulmonology.ru/pulm/article/view/1202

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1202
https://doi.org/10.18093/0869-0189-2019-29-4-486-492